Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Adverse effects
RCT	45 people with suspected PCP, 38 people with confirmed PCP (only those with confirmed diagnoses and who gave consent were evaluated further)	Major adverse effects requiring cessation of treatment 0/17 (0%) with aerosolised pentamidine 600 mg daily 3/21 (14%) with intravenous pentamidine 3 mg/kg daily	P = 0.24		Not significant
RCT	45 people with suspected PCP, 38 people with confirmed PCP (only those with confirmed diagnoses and who gave consent were evaluated further)	Major toxicity 0/17 (0%) with aerosolised pentamidine 600 mg daily 3/21 (14%) with intravenous pentamidine 3 mg/kg daily	Rate difference +0.14 95% CI −1 to +29 P = 0.24		Not significant
RCT	45 people with suspected PCP, 38 people with confirmed PCP (only those with confirmed diagnoses and who gave consent were evaluated further)	Minor toxicity 2/17 (12%) with aerosolised pentamidine 600 mg daily 8/21 (38%) with intravenous pentamidine 3 mg/kg daily	Rate difference +0.26 95% CI −1.00 to +52.00 P = 0.14		Not significant